Bifikafusp alfa/onfekafusp alfa
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Bifikafusp alfa | Protein |
| Onfekafusp alfa | Protein |
| Clinical data | |
| ATC code | |
Bifikafusp alfa/onfekafusp alfa is an experimental cancer treatment intended for the treatment of melanoma.[1] It contains bifikafusp alfa and onfekafusp alfa.[1]
Bifikafusp alfa consists of interleukin-2 (IL-2), a naturally occurring protein that activates certain white blood cells that can recognize and attack cancer cells.[1] Bifikafusp alfa is linked to L19, another protein which was expected to enable the medicine to target cancer cells and not healthy tissue.[1][2] Onfekafusp alfa consists of tumor necrosis factor which disrupts the blood supply to the tumor, and is also linked to L19.[1][3]
